Kenneth Aldape, MD, is the head of the MacFeeters-Hamilton Brain Tumour Centre at Princess Margaret Cancer Centre/Ontario Cancer Institute. He received his doctoral degree from the University of California, School of Medicine, San Francisco, completed a residency and postdoctoral training at the University of California, San Francisco. His research interests include gliomas, molecular genetics, and clinical genomics.
Michael G. Espey, PhD, is a Program Director in the National Cancer Institute’s Division of Cancer Biology. Dr. Espey manages a diverse portfolio of grants that focus on redox mechanisms, mitochondria, and cancer stem cells; he also develops and assists in the management of scientific projects in the Physical Sciences – Oncology Network. Dr. Espey is Board certified in clinical pathology with prior experience at the University of Iowa Hospital, Georgetown University Hospital, and the NIH Clinical Center in Hematology, Immunology, Microbiology, Transfusion Medicine, and Organ Transplant. He received his PhD with distinction from Georgetown University jointly in Biology and Physiology. As a NIH intramural staff scientist in both NCI and NIDDK, he conducted basic, pre-clinical, and translational research on innate immunology, infectious disease, radiation biology, and cancer–tumor microenvironment redox mechanisms, in particular the interplay between oxygen, nitric oxide, and associated reactive species in terms of cancer biology and therapeutic interventions. Dr. Espey has strong interests in imaging, biophysical instrumentation, and drug development and is the NIH FAES Professor for Molecular and Cellular Biology.
Arnold J. Levine, PhD, is a Professor of Systems Biology at the Institute for Advanced Study in Princeton New Jersey. A renowned researcher in cancer research, Levine and others discovered the p53 tumor suppressor protein, a molecule that inhibits tumor development. He established the Simons Center for Systems Biology at the Institute, which concentrates on research at the interface of molecular biology and the physical sciences. Their areas of interest include genetics and genomics, polymorphisms and molecular aspects of evolution, signal transduction pathways and networks, stress responses, and pharmacogenomics in cancer biology.
Robert D. MacPherson, PhD, is an American mathematician at the Institute for Advanced Study and Princeton University. He is best known for the invention of intersection homology with Mark Goresky, at Brown University. MacPherson previously taught at Brown University, the University of Paris, and the Massachusetts Institute of Technology. Educated at Swarthmore College and Harvard University, MacPherson received his PhD from Harvard in 1970. His thesis, written under the direction of Raoul Bott, was entitled Singularities of Maps and Characteristic Classes. Among his many PhD students are Kari Vilonen and Mark Goresky. Recently MacPherson has become interested in applications of topology to complex systems.
Konstantin Mischaikow, PhD is a Distinguished Professor in the Mathematics Department at Rutgers University. He previously taught at Michigan State University and Georgia Institute of Technology. Mischaikow received his doctoral degree in Mathematics from the University of Wisconsin, Madison. The focus of his research is on developing mathematical and computational methods for analyzing complex nonlinear systems arising from differential equations or time series data.
Do-Hyun Nam, MD is the Director of the Institute of Refractory Cancer, Samsung Medical Center and the Chairman of the Graduate School for Health Sciences & Technology, Sungkyunkwan University School of Medicine. Dr. Nam has extensive expertise in brain tumor research. His major scientific achievements include the creation of AVATAR System, which recommends effective therapeutic options for individual patients based on tumors’ genomic alterations and drug response profiles. His research team has established processes for genomic characterization of longitudinal samples, patient-matched culture and xenograft models (AVATAR Mouse®), drug response screening in culture models (AVATASCAN®), and drug response validation in xenograft models. Using this AVATAR system, Dr. Nam is currently working on genome-based, patient-centered clinical trials for personalized therapy. In addition, he has made notable advances in research of adult human neural stem cells and the development of novel therapies for neurological diseases.